- Tornier
- About Tornier
- Product Information
Select a Country for Availability
- Australia
- France
- Germany
- Italy
- Netherlands
- Spain
- Switzerland
- United Kingdom
- United States
- Other Countries
- News
- Investor Relations
AMSTERDAM, The Netherlands – May 9, 2013
Of the 7.0 million ordinary shares being sold in the offering, 4.5 million shares are being sold by Tornier and 2.5 million shares are being sold by certain existing shareholders. The selling shareholders include funds associated with affiliates of Warburg Pincus LLC and
Tornier expects to use the net proceeds from the sale of the newly issued shares for working capital, repayment and refinancing of debt and general corporate purposes, including clinical and product development, capital expenditures and the acquisition of technologies, products or businesses. Tornier will not receive any of the proceeds of the ordinary shares being sold by the selling shareholders.
A shelf registration statement relating to the sale of these securities has been filed with the
Tornier is a global medical device company focused on serving extremities specialists who treat orthopaedic conditions of the shoulder, elbow, wrist, hand, ankle and foot. The Company's broad offering of over 100 product lines includes joint replacement, trauma, sports medicine, and ortho-biologic products through Tornier and OrthoHelix brands to treat the extremities, as well as joint replacement products for the hip and knee in certain international markets. Since its founding approximately 70 years ago, Tornier's "Specialists Serving Specialists" philosophy has fostered a tradition of innovation, intense focus on surgeon education, and commitment to advancement of orthopaedic technology stemming from its close collaboration with orthopaedic surgeons and thought leaders throughout the world.
Statements contained in this release that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations of future events and often can be identified by words such as "expect," "should," "project," "anticipate," "intend," "will," "may," "believe," "could," "would," "continue," "outlook," "guidance," "future," "prospects," other words of similar meaning or the use of future dates. Examples of forward-looking statements in this release include Tornier's expectations regarding the offering, including the actual size or terms of the offering, the size of the underwriter's option to purchase additional ordinary shares, whether or when the offering may be completed and its anticipated use of proceeds from the offering. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Tornier's actual results to be materially different than those expressed in or implied by Tornier's forward-looking statements. For Tornier, such uncertainties and risks include, among others, risks associated with the offering, Tornier's future operating results and financial performance, fluctuations in foreign currency exchange rates, the effect of global economic conditions, the European sovereign debt crisis, and austerity measures, risks associated with Tornier's international operations and expansion, risks associated with Tornier's recent acquisition of OrthoHelix and subsequent integration activities, changes in Tornier's arrangements with its distributors and independent sales agencies and transition to direct selling models in certain geographies and territories, the timing of regulatory approvals and introduction of new products, physician acceptance, endorsement, and use of new products; the effect of regulatory actions, changes in and adoption of reimbursement rates, potential product recalls, competitor activities, Tornier's leverage and access to credit under its credit facility agreement, and the costs and effects of litigation and changes in tax and other legislation. More detailed information on these and other factors that could affect Tornier's actual results are described in Tornier's filings with the
Chief Financial Officer
(952) 426-7646
shawn.mccormick@tornier.com
May 9, 2013
Tornier Announces Pricing of Public Offering of Ordinary Shares
May 7, 2013
Tornier Reports First Quarter 2013 Results
May 7, 2013
Tornier Announces Follow-on Offering of Ordinary Shares
April 26, 2013
Tornier to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
April 3, 2013
Tornier Announces First Quarter 2013 Conference Call
February 21, 2013
Tornier Names David H. Mowry President and Chief Executive Officer
February 21, 2013
Tornier Reports Fourth Quarter and Fiscal Year 2012 Results and Provides 2013 Outlook
February 11, 2013
Tornier to Present at the 2013 RBC Capital Markets Global Healthcare Conference
January 7, 2013
Tornier Reiterates Fourth Quarter and Full Year 2012 Revenue Guidance
November 12, 2012
Tornier Appoints David H. Mowry as Interim President and Chief Executive Officer
November 5, 2012
Tornier Reports Third Quarter 2012 Financial Results
November 1, 2012
Tornier to Present at the Credit Suisse 2012 Healthcare Conference
October 17, 2012
Tornier Announces Third Quarter 2012 Conference Call
August 24, 2012
Tornier to Acquire OrthoHelix Surgical Designs
August 7, 2012
Tornier Reports Second Quarter 2012 Financial Results
July 18, 2012
Tornier Appoints New Chief Financial Officer
July 17, 2012
Tornier Announces Second Quarter 2012 Conference Call
June 12, 2012
Tornier to Present at the Wells Fargo Securities Research and Economics 2012 Healthcare Conference
May 8, 2012
Tornier Reports First Quarter 2012 Financial Results
May 1, 2012
Tornier to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
April 13, 2012
Tornier Announces 2012 Facility Consolidations
February 23, 2012
Tornier Reports 2011 Financial Results and Provides 2012 Outlook
February 21, 2012
Tornier to Present at the 2012 RBC Capital Markets Healthcare Conference
February 8, 2012
Tornier to Highlight Products and Education Programs at American Academy of Orthopedic Surgeons (AAOS) Meeting
January 9, 2012
Tornier Announces Preliminary Fourth Quarter Sales Gain of 12.7% and Full Year 2011 Sales Gain of 14.9%
December 23, 2011
Tornier to Present at the 30th Annual J.P. Morgan Healthcare Conference
November 8, 2011
Tornier Reports Third Quarter 2011 Financial Results
August 9, 2011
Tornier Reports Second Quarter 2011 Financial Results
August 2, 2011
Tornier Announces First Implant in U.S. Clinical Study for the Simpliciti™ Stemless Shoulder Joint Replacement System
July 13, 2011
Tornier Announces Conference Call Of Second Quarter Results
May 19, 2011
Tornier Introduces Porous Coated Affiniti™ Stem for Shoulder Joint Replacement Surgery
May 9, 2011
Tornier Reports First Quarter 2011 Financial Results
April 19, 2011
Tornier Announces Conference Call of First Quarter Results
April 14, 2011
Tornier Announces Launch of BioFiber® Surgical Mesh for Tendon Repair at Arthroscopic Surgery Conference
March 7, 2011
Tornier Announces Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares in IPO
March 1, 2011
Tornier Reports Financial Results for 2010 and Provides 2011 Outlook
February 15, 2011
Tornier to Highlight Six New Products at American Academy of Orthopaedic Surgeons (AAOS) Meeting
February 15, 2011
Tornier Announces Conference Call of Fourth Quarter and Year End 2010 Results
February 8, 2011
Tornier Completes Initial Public Offering
February 2, 2011
Tornier Prices Initial Public Offering